Condition: Safety · Tolerability · GenSci098 · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
This description comes directly from the study's public registry record.
Zhongyan Shan, PHD · +86 24 8328 2152 · shanzhongyan@hotmail.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07286656